-  INCLUSION CRITERIA:

          -  Patients must have histologically or cytologically confirmed, previously untreated
             intermediate/high risk, p16-negative (if oropharyngeal primary tumor), squamous cell
             carcinoma of the head and neck (T1-T4, N0-N3, M0 stage II, III or IV).

          -  Male or female; Age greater than or equal to 18 years.

          -  ECOG performance status less than or equal to 1.

          -  Prothombin time (PT) and partial thromboplastin time (PTT) within normal institutional
             limits. Patients with prolonged PTT determined to be due to lupus anticoagulant will
             not be excluded.

          -  Patients must have adequate organ and marrow function as defined below:

               -  Absolute neutrophil count greater than or equal to 1000/mcL

               -  Platelets greater than or equal to 100,000/mcL

               -  Hemoglobin greater than or equal to 10.0 g/dL

               -  Total bilirubin within normal institutiona l limits; in patients with Gilbert s,
                  less than or equal to 3.0 mg/dL

               -  AST (AGOT)/ALT (AGPT) less than or equal to 3X upper limit of normal.

               -  Creatinine within 1.5X upper limit of normal institutional limits

          -  The effects of M7824, TriAd vaccines, and N-803 on the developing human fetus are
             unknown. For this reason, men and women of child bearing capacity must agree to use
             highly-effective contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, during the study and maintain such contraception
             until 2 months following the last dose of any study agent. Should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document

          -  Patients with successfully treated hepatitis C virus (HCV) are eligible if HCV viral
             load is undetectable.

        EXCLUSION CRITERIA:

          -  Patients who are immunocompromised as follows:

               -  Human immunodeficiency virus (HIV) positive patients not on or not compliant with
                  appropriate anti-retroviral therapy, patients with newly diagnosed (i.e. < 6
                  months) HIV, patients with an HIV viral load exceeding 400 copies/mL, HIV+
                  patients with a CD4 count < 150 cells/ L, and HIV+ patients on antiretroviral
                  therapy < 1 month are excluded. HIV-positive patients will also be excluded if
                  the PI determines that there is a clinically significant drug-drug interaction.

               -  Chronic administration (defined as daily or every other day for continued use >14
                  days) of systemic corticosteroids or other immune suppressive drugs, within 14
                  days before treatment on study. Physiologic daily dosing of steroids is allowed.
                  Nasal, or inhaled steroid, topical steroid creams and eye drops for small body
                  areas are allowed.

               -  Patients who have undergone allogeneic peripheral stem cell transplantation, or
                  solid organ transplantation requiring immunosuppression

          -  Pregnant women are excluded from this study because M7824 is an agent with the
             potential for teratogenic or abortifacient effects. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with M7824 breastfeeding should be discontinued if the mother is treated with
             M7824. These potential risks may also apply to other agents used in this study.

          -  Patients with active systemic autoimmune disease, except patients with type 1 diabetes
             mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring current
             immunosuppression, or with other endocrine disorders on replacement hormones, are not
             excluded if the condition is well controlled.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study agents to be used in the cohort the subject will be enrolled
             into.

          -  Known allergy to eggs, egg products, aminoglycoside antibiotics (for example,
             gentamicin or tobramycin). Patients enrolling on the M7824 only arm will be exempt
             from this exclusion.

          -  Patients with a history of bleeding diathesis or recent clinically significant
             bleeding events considered by the Investigator as high risk for investigational drug
             treatment are excluded.

          -  Any condition which, in the opinion of the investigator, would prevent full
             participation in this trial (including the long-term follow-up), or would interfere
             with the evaluation of the trial endpoints.

          -  Patients with prior live vaccine, investigational drug, chemotherapy, immunotherapy or
             any prior radiotherapy (except for palliative bone directed therapy) within the past
             28 days prior to enrollment.

          -  Uncontrolled intercurrent acute or chronic illness including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure (>New York Heart
             Association Class I), hepatic disease, unstable angina pectoris, serious cardiac
             arrhythmia, requiring medication, uncontrolled hypertension (SBP>170/ DBP>105) or
             psychiatric illness/social situations within 12 months that would limit compliance
             with study requirements.

          -  Patients who have undergone major surgery within 4 weeks prior to enrollment. A biopsy
             will not preclude a patient from starting study.

          -  Patients with a history of hepatitis B (HBV) are excluded due to potential risk for
             viral reactivation and resulting liver injury in persons with latent HBV.

          -  Patients with treated or active brain metastases are not eligible because we are
             enrolling non-metastatic head and neck cancer patients in this trial. Standard of care
             treatment is different for head and neck cancer patients with and without metastatic
             disease.